Sign in

CIK 0001721484

  • Emerging growth company

Longeveron Inc.

Sign in to watch
Ticker
LGVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
472174146
Phone
+1 305-302-7158
Business address
1951 NW 7TH AVENUE, SUITE 520, MIAMI, FL, 33136
Former names
LONGEVERON LLC
  1. 4 Shares withheld for taxes CFO and Treasurer gave up 1,288 shares (to pay taxes)
  2. 4 Grant or award Chief Medical Officer acquired 152,335 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Grant or award Director acquired 5,000 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Shares withheld for taxes CFO and Treasurer gave up 1,736 shares (to pay taxes)
  7. 4 Shares withheld for taxes General Counsel, Secretary gave up 3,316 shares (to pay taxes)
  8. 4 Shares withheld for taxes CEO gave up 3,979 shares (to pay taxes)
  9. 4 Open-market buy Chief Scientific Officer bought 2,500 shares at $3.69 ($9,225)
  10. 4 Open-market buy CEO bought 1,000 shares at $3.81 ($3,810)
  11. 4 Open-market buy Director bought 19,900 shares at an average $3.66 ($72,855)
  12. 4 Open-market buy CFO and Treasurer bought 5,000 shares at $3.34 ($16,700)
  13. 4 Open-market buy General Counsel, Secretary bought 1,750 shares at $3.34 ($5,845)
  14. 4 Open-market buy Chief Scientific Officer bought 5,000 shares at an average $3.39 ($16,930)
  15. 4 Shares withheld for taxes General Counsel, Secretary gave up 38,752 shares (to pay taxes)
  16. 4 Shares withheld for taxes CFO and Treasurer gave up 19,052 shares (to pay taxes)
  17. 4 Shares withheld for taxes CEO gave up 43,929 shares (to pay taxes)
  18. 4 Grant or award CEO acquired 8,223 shares (grant or award)
  19. 4 Grant or award General Counsel, Secretary acquired 6,167 shares (grant or award)
  20. 4 Grant or award Chief Scientific Officer acquired 12,335 shares (grant or award)

Page 11 of 13 · 246 filings